Literature DB >> 10048764

Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis.

L A Goldman1, M Zafari, E C Cutrone, A Dang, M Brickelmeier, L Runkel, C D Benjamin, L E Ling, J A Langer.   

Abstract

The type I interferon receptor (IFNAR) is composed of two subunits, IFNAR-1 and IFNAR-2, encoding transmembrane polypeptides. IFNAR-2 has a dominant role in ligand binding, but IFNAR-1 contributes to binding affinity and to differential ligand recognition. A panel of five monoclonal antibodies (mAb) to human IFNAR-1 (HuIFNAR-1) was produced and characterized. The reactivity of each mAb toward HuIFNAR-1 on native and transfected cells and in Western blot and ELISA formats was determined. In functional assays, one mAb, EA12, blocked IFN-a2 binding to human cells and interfered with Stat activation and antiviral activity. Epitopes for the mAb were localized to subdomains of the HuIFNAR-1 extracellular domain by differential reactivity of the mAb to a series of human/bovine IFNAR-1 chimeras. The antibody EA12 seems to require native HuIFNAR-1 for reactivity and does not map to a single subdomain, perhaps recognizing an epitope containing noncontiguous sequences in at least two subdomains. In contrast, the epitopes of the non-neutralizing mAb FB2, AA3, and GB8 mapped, respectively, to the first, second, and third subdomains of HuIFNAR-1. The mAb DB2 primarily maps to the fourth subdomain, although its reactivity may be affected by other determinants.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10048764     DOI: 10.1089/107999099314379

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  25 in total

Review 1.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

2.  Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis.

Authors:  Hui Zheng; Juan Qian; Christopher J Carbone; N Adrian Leu; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-10       Impact factor: 22.113

3.  Ligand-independent pathway that controls stability of interferon alpha receptor.

Authors:  Jianghuai Liu; Alexander Plotnikov; Anamika Banerjee; K G Suresh Kumar; Josiane Ragimbeau; Zrinka Marijanovic; Darren P Baker; Sandra Pellegrini; Serge Y Fuchs
Journal:  Biochem Biophys Res Commun       Date:  2007-12-31       Impact factor: 3.575

4.  Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor.

Authors:  Hui Zheng; Juan Qian; Darren P Baker; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

5.  Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2.

Authors:  Hui Zheng; Juan Qian; Bentley Varghese; Darren P Baker; Serge Fuchs
Journal:  Mol Cell Biol       Date:  2010-12-20       Impact factor: 4.272

6.  An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Authors:  Angelica Ortiz; Jun Gui; Farima Zahedi; Pengfei Yu; Christina Cho; Sabyasachi Bhattacharya; Christopher J Carbone; Qiujing Yu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Simran Handa; Victor Haas; Susan W Volk; Angela K Brice; Kim Wals; Nicholas J Matheson; Robin Antrobus; Sonja Ludwig; Theresa L Whiteside; Cindy Sander; Ahmad A Tarhini; John M Kirkwood; Paul J Lehner; Wei Guo; Hallgeir Rui; Andy J Minn; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2019-01-14       Impact factor: 31.743

7.  Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

Authors:  K G Suresh Kumar; Jianghuai Liu; Ying Li; Duonan Yu; Andrei Thomas-Tikhonenko; Meenhard Herlyn; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2007-06-13       Impact factor: 4.742

8.  Inducible priming phosphorylation promotes ligand-independent degradation of the IFNAR1 chain of type I interferon receptor.

Authors:  Sabyasachi Bhattacharya; Wei-Chun HuangFu; Jianghuai Liu; Sudhakar Veeranki; Darren P Baker; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

9.  Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.

Authors:  Jun Gui; Michael Gober; Xiaoping Yang; Kanstantsin V Katlinski; Christine M Marshall; Meena Sharma; Victoria P Werth; Darren P Baker; Hallgeir Rui; John T Seykora; Serge Y Fuchs
Journal:  J Invest Dermatol       Date:  2016-06-29       Impact factor: 8.551

10.  The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

Authors:  Josiane Ragimbeau; Elisabetta Dondi; Andrés Alcover; Pierre Eid; Gilles Uzé; Sandra Pellegrini
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.